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In vitro studies showed that 1-(propan-2-ylamino)-4-propoxy-9H-thioxanthen-9-one (TX5) 
increases P-glycoprotein (P-gp) expression and activity in Caco-2 cells, preventing xenobiotic 
toxicity. The present study aimed at investigating TX5 effects on P-gp expression/activity using 
Wistar Han rats: a) in vivo, evaluating intestinal P-gp activity; b) ex vivo, evaluating P-gp 
expression in ileum brush border membranes (BBM) and P-gp activity in everted intestinal 
sacs; c) ex vivo, evaluating P-gp activity in everted intestinal sacs of the distal and proximal 
ileum. TX5 (30 mg/kg, b.w.), gavage, activated P-gp in vivo, given the significant decrease in the 
AUC of digoxin (0.25 mg/kg, b.w.). The efflux of rhodamine 123 (300 M), a P-gp fluorescent 
substrate, significantly increased in TX5-treated everted sacs from the distal portion of the rat 
ileum, when P-gp activity was evaluated in the presence of TX5 (20 M), an effect abolished by 
the P-gp inhibitor verapamil (100 M). No increases on P-gp expression or activity were found 
in TX5-treated BBM of the distal ileum and everted distal sacs, respectively, 24 hours after TX5 
(10 mg/kg, b.w.) administration. In vivo, no differences were found on digoxin portal 
concentration between control (digoxin 0.025 mg/kg, b.w., intraduodenal) and TX5-treated 
(digoxin+TX5 20 M, intraduodenal) rats. The observed discrepancies in digoxin results can be 
related to differences in TX5 dose administered and used methodologies.  Thus, the results 
show that TX5 activates P-gp at the distal portion of the rat ileum, and, at the higher dose 
tested (30 mg/kg, b.w.), seems to modulate in vivo the AUC of P-gp substrates.  
 

















Permeability glycoprotein (P-glycoprotein; P-gp), encoded by the multidrug resistant gene 1 
(MDR1 or ABCB1), is a carrier protein that belongs to the ATP-binding cassette (ABC) 
superfamily of membrane transporters and which activity, against a concentration gradient, 
depends on ATP hydrolysis (Gameiro et al., 2017). P-gp was originally identified in cancer cells 
resistant to chemotherapeutic drugs, reason by which it is also known as multidrug resistance 
protein-1 (MDR-1) (Juliano and Ling, 1976). P-gp promotes the efflux of both endo- and 
xenobiotics, thus protecting cells against their biological effects, namely toxicity (Silva et al., 
2015b). In fact, P-gp has a broad substrate specificity, being able to bind structural and 
pharmacologically unrelated hydrophobic drugs, such as cardiac glycosides, calcium channel 
blockers, anticancer and immunosuppressant agents (Gottesman et al., 2002; Silva et al., 
2015a).  
P-gp is a transmembrane glycoprotein, showing a polarized expression in a variety of tissues 
(including the intestine, liver, lungs, kidneys) and body barriers (placenta, blood-brain and 
blood-testis barriers), both in physiological and pathological conditions. Particularly, P-gp is 
overexpressed in the blood-brain barrier, gastrointestinal tract, kidneys, liver, pancreas and 
cancerous cells (Gupta et al., 2015). P-gp activity can be modulated by inhibitors, inducers 
and/or activators, in order to increase or decrease, respectively, drugs intracellular 
accumulation (Gameiro et al., 2017).  
Under the toxicological point of view, P-gp induction and/or activation could constitute an 
effective therapeutic strategy to detoxify the body from harmful compounds. In fact, Dinis-
Oliveira and co-authors proposed P-gp induction in pneumocytes as a valuable therapeutic 
approach to increase the efflux of paraquat, a well-known toxic P-gp substrate (Dinis-Oliveira 
et al., 2006a; Dinis-Oliveira et al., 2006b). Additionally, several studies using in vitro models 
were performed showing a protective effect resulting from the increase of the de novo 
synthesis of P-gp, but also from the increase of its activity, which reduced the cytotoxicity 













2014b; Silva et al., 2011b; Vilas-Boas et al., 2013). Some of these studies used thioxanthones 
(TXs), which are S-heterocycles with a dibenzo--thiopyrone scaffold and constitute a class of 
compounds able to modulate P-gp activity (Lima et al., 2016; Paiva et al., 2013; Palmeira et al., 
2012). In our previous in vitro study (Silva et al., 2015a), it was demonstrated that the 1-
(propan-2-ylamino)-4-propoxy-9H-thioxanthen-9-one (TX5) can reduce paraquat-mediated 
toxicity in Caco-2 cells as a consequence of P-gp induction (increased expression levels) and 
activation (increased activity). Based on this promising result, we decided to continue the 
study of TX5 by evaluating its putative modulatory role over P-gp expression and activity, both 
ex vivo and in vivo, focusing at the intestinal barrier. For that, we selected a 30 mg/kg (b.w.) 
dose of the compound for a preliminary in vivo efficacy study, whose results are herein 
presented. Given the motivating results obtained, we proceeded to a safety assessment of the 
compound (Rocha-Pereira et al., 2019), which led us to reduce the dose to 10 mg/kg (b.w.) to 
be administered, by gavage, in the subsequent ex vivo functional assays described in the 
present work. Direct effects of TX5 (20 M) on P-gp expressed in the intestine, in ex vivo and in 
vivo studies, were also assessed.  
Our main goal is to find compounds capable of increasing P-gp activity and/or expression in 
vivo. By studing P-gp inducers/activators as TX5, these ones can be used as xenobiotic safety 
enhancers through their ability to decrease the absorption of potentially toxic compounds  at 


















MATERIALS AND METHODS  
Chemicals and drugs 
Rhodamine 123 (RHO 123), digoxin, verapamil, sodium chloride, bovine serum albumin (BSA), 
Tris hydrochloride, Tris base, phenylmethylsulfonyl fluoride (PMSF) and mannitol were 
obtained from Sigma-Aldrich (Saint Louis, Missouri, USA). Meanwhile, cOmplete™ Protease 
Inhibitor Tablets were purchased from Roche (Amadora, Portugal). Ethanol was obtained from 
Aga (Prior Velho, Portugal) and Hepes from Fisher Scientific (Geel, Belgium). Ketamine and 
xylazine were obtained from Novavet (Bragança, Portugal). Meanwhile, isoflurane (Isoflo®) 
was purchased from Abbott (IL, USA) and lidocaine 25 mg/g + Prilocaine 25 mg/g (EMLA®) was 
acquired from AstraZeneca (London, UK). Heparin was acquired from Braun (Germany). 
Dimethyl sulfoxide (DMSO), potassium chloride, sodium hydrogenocarbonate, potassium 
dihydrogen phosphate, calcium chloride and glucose were purchased from Merck (Darmstadt, 
Germany). Magnesium sulfate heptahydrate was from Labkem (Barcelona, Spain). TX5 was 
synthesized by the Organic and Pharmaceutical Chemistry Laboratory of the Faculty of 
Pharmacy of University of Porto, according to described procedures (Palmeira et al., 2012). An 
ethyl ether solution was prepared with TX5 (purity > 95 %) and was cooled at - 4 °C. A solution 
of hydrogen chloride 2.0 M in diethyl ether solution (1 ml) was added. An orange precipitate 
was formed and it was placed at - 4 °C overnight. The solid thus obtained was filtered, washed 
with 100 ml of diethyl ether, and dried in a desiccator containing phosphorus pentoxide 
furnishing 1-(propan-2-ylamino)-4-propoxy-9H-thioxanthen-9-one hydrochloride (TX5.HCl). 
Stock solutions were made up in ultrapure water or DMSO and diluted in Krebs-Henseleit 
buffer or saline solution (0.9 % NaCl) immediately before use. DMSO was added to the Krebs-
Henseleit solution in parallel control experiments. All the reagents used were of analytical 















Adult male Wistar Han rats (12-16-week-old) were purchased from Charles River Laboratories 
(Barcelona, Spain). Animals were kept under standard laboratory conditions (12/12 h 
light/dark cycles, 22 ± 2 °C room temperature, 50 – 60 % humidity) for an acclimation period of 
at least 1 week before starting experiments. During this period, animals had free access to tap 
water and rat chow ad libitum. Animal experiments were approved by the Organismo 
Responsável pelo Bem-Estar Animal (ORBEA; protocol number 250/2018) from the Institute of 
Biomedical Sciences Abel Salazar of University of Porto (ICBAS-UP). Housing and experimental 
treatment of the animals were in accordance with the guidelines defined by the European 
Council Directive for animal experiments (2010/63/EU) and the current Portuguese Law 
(Decreto-Lei no. 113/2013, de 7 de Agosto). 
 
Experimental protocol 
Assessment of P-glycoprotein transport activity in vivo after administration of TX5 by gavage 
To assess P-gp activity in vivo, we started by carrying out a first assay in which a 30 mg/kg 
(b.w.) dose of TX5 hydrochloride was tested. The selection of this dose was based on a 
previous in vivo study recently reported by Lima and colleagues (Lima et al., 2018) in which 
increasing doses of a TX5-like compound, TXA1, administered subcutaneously, three times per 
week, for two weeks, did not cause evident signs of rat discomfort until the dose of 50 mg/kg. 
Animals were kept in standard cages and groups allowing social interactions. Eighteen animals 
were fasted for 12 h prior administration, by gavage, of digoxin (0.25 mg/kg b.w.), a well-
known P-gp substrate, or digoxin+TX5 hydrochloride (0.25 mg/kg b.w. + 30 mg/kg b.w.). 
Immediately before the administration of the compound(s) by gavage, each animal was 













to the administration (Murphy et al., 2001). Each animal was locally anesthetized with a 
mixture of lidocaine (2.5 %) and prilocaine (2.5 %) (EMLA® cream), applied in the rat tail 30 
minutes prior blood collection (Flecknell et al., 1990). Blood was collected from caudal vein at 
different time points during seven hours and local anesthesia was reapplied between each 
sampling. Blood was then centrifuged (1670 x g, 10 min, room temperature) and the obtained 
plasma samples were stored at -20 °C until further analysis. Digoxin concentration in plasma 
samples was measured on an AutoAnalyzer (PRESTIGE® 24i, PZ Cormay S.A.), using the 
respective kit and following the manufacturer instructions. 
 
P-glycoprotein expression assessment at the intestinal barrier 
Distal ileum collection and brush border membrane preparation 
Animals were maintained in standard cages and groups allowing social interactions. Animals 
were fasted for 4 h before administration of TX5 hydrochloride (10 mg/kg, b.w.) or water 
(vehicle), by gavage. Each animal was subjected to a brief inhalatory anesthesia with isoflurane 
to reduce the discomfort associated to the administration. TX5 hydrochloride was prepared at 
the day of use in ultrapure water. A maximum volume of 1 ml was administered per 200 g b.w. 
Control animals received ultrapure water using equivalent administration volumes of TX5-
treated animals. Animals were fasted for the last 12 h prior experiments, but water 
supplemented with 1 % sugar was given ad libitum. Twenty-four hours after TX5 or water 
administration, rats were anesthetized with a mixture of ketamine and xylazine (90/10 mg/kg 
b.w., respectively, ip) and placed in decubito supino position. The abdomen was opened and 
the distal portion of the ileum was selected as the last 20 cm close to the ileocecal valve. The 
segments were gently rinsed with ice-cold saline solution (0.9 % NaCl) containing 0.4 % PMSF 
40 g/ml, and immediately used for the isolation of brush border membranes (BBM). To 













using the methodology described by Kessler and colleagues (Kessler et al., 1978) for the 
preparation of brush border membranes from small intestine, with minor modifications 
introduced and validated by Mottino and co-authors (Mottino et al., 2000). Briefly, the 
intestinal segments were opened lengthwise, the mucus layer was carefully removed and the 
mucosa was scraped from the wall. The tissue thus obtained was used for BBM preparation. 
Mucosa samples were homogenized in buffer [buffer A: 50 mM mannitol, 2 mM Tris/HCl, 
cOmplete™ Protease Inhibitor Tablets (one tablet per 25 ml buffer)] and BBM were prepared 
from total homogenate by a divalent cation precipitation method followed by differential 
centrifugation (21 000 x g, 1 hour at 4 °C). The final pellet was ressuspended in buffer (buffer 
B: 300 mM mannitol, 10 mM HEPES, 10 mM Tris base, cOmplete™ Protease Inhibitor Tablets). 
Aliquots of BBM preparations were used for Western blot analysis. Protein concentration in 
membrane preparations was measured using BSA as standard (Lowry et al., 1951). 
 
Western blot analysis of P-glycoprotein 
The western blot analysis of P-gp expression was performed on BBM of the distal portion of  
the ileum of control and TX5-treated rats obtained after exposure of animals to TX5 (10 mg/kg 
b.w.) for 24 h. This dose was selected after a preliminary safety assessment of TX5 (Rocha-
Pereira et al., 2019). Detection of P-gp was performed using an anti-P-gp C219 mouse 
monoclonal primary antibody from Calbiochem (Calbiochem®, Merck KGaA, Darmstadt, 
Germany) validated for use in immunoblotting. 
After assessment of the total protein content, using the Bio-Rad DC protein assay (Bio-Rad 
Laboratories, Hercules, CA, USA) and BSA as standard, samples were diluted to equal protein 
concentration, and 120 μL were mixed with 30 μL SDS-PAGE reducing buffer [11.5 % SDS (w/v), 
62.5 mM Tris HCl (pH 6.8), 50 % glycerol (v/v), 1 % bromophenol blue (w/v) and 25 % β-













SDS/polyacrylamide gels, at a constant voltage of 150 mV, using a running buffer [25 mM Tris 
Base, 192 mM glycine and 0.1 % SDS (w/v), pH 8.6]. Gels were allowed to equilibrate in  
transfer buffer [20 % methanol (v/v) in 25 mM Tris Base and 192 mM glycine, pH 8.3] and then 
transferred to nitrocellulose membranes (Hybond ECL, Amersham Pharmacia Biotech, 
Buckinghamshine, United Kingdom), at a constant amperage of 290 mA, for 90 min. 
Membranes were then rinsed in Tris-buffered saline solution with Tween 20 [TBS-T: 20 mM 
Tris base, 300 mM NaCl and 5 % Tween 20 (v/v), pH 8.0], and nonspecific sites were blocked 
for 1 h, at room temperature, in blocking buffer [5 % skim milk (w/v) in TBS-T]. Membranes 
were then incubated with primary antibodies (overnight at 4 °C): C219 mouse monoclonal anti-
P-gp (1:1000) and mouse polyclonal anti-tubulin (1:2500, Sigma-Aldrich, Saint Louis, Missouri, 
USA), prepared in 3 % skim milk (w/v) in TBS-T blocking buffer. Tubulin was used as a protein 
loading control. After washing three times (10 min each) with TBS-T, the membranes were 
incubated with the anti-mouse peroxidase secondary antibody (1:2000, Amersham Pharmacia 
Biotech), prepared in 3 % skim milk (w/v) in TBS-T blocking buffer, for 2 h, at room 
temperature, under mild shaking. Following three washes (10 min each) with TBS-T, 
immunoreactive bands were detected using the Clarity™ Western ECL Substrate (Bio-Rad 
Laboratories), according to the supplier`s instructions, and digital images were acquired using 
a Molecular Imager® ChemiDoc™ XRS + System (Bio-Rad Laboratories) and analyzed with 
ImageLab™ 6.0 Software (Bio-Rad Laboratories, Berkeley, CA, USA).  
 
Assessment of P-glycoprotein transport activity in everted intestinal sacs 
The TX5 effect on P-gp activity was evaluated, ex vivo, by using two distinct protocols, i.e., 
either 24 h after TX5 hydrochloride administration (10 mg/kg b.w., by gavage) or after an acute 
and direct contact with TX5 (20M), using everted intestinal sacs and rhodamine 123 (RHO 













Assessment of P-glycoprotein transport activity in everted intestinal sacs of Wistar Han rats 
pre-exposed to TX5 for 24 h 
Animals were maintained in standard cages and groups allowing social interactions. Animals 
were fasted for 4 h before administration of TX5 hydrochloride (10 mg/kg, b.w.) or water 
(vehicle), by gavage. Each animal was subjected to a brief inhalatory anesthesia with isoflurane 
to reduce the discomfort associated to the administration. TX5 hydrochloride was prepared at 
the day of use in ultrapure water. A maximum volume of 1 ml was administered per 200 g b.w. 
Control animals received ultrapure water using equivalent administration volumes of TX5-
treated animals. Animals were fasted for the last 12 h prior experiments, but water 
supplemented with 1 % sugar was given ad libitum. Twenty-four hours after TX5 or water 
administration, rats were anesthetized with a mixture of ketamine and xylazine (90/10 mg/kg 
b.w., respectively, ip) and placed in decubito supino position. The abdomen was opened, the 
ileocecal valve was identified and the distal portion of the ileum was removed (20 cm 
approximately). The segments were gently rinsed with ice-cold saline solution (0.9 % NaCl) and 
immediately used to prepare everted intestinal sacs using an ice-cold plate. Each intestinal sac 
(10 cm approximately) was placed in a chamber containing Krebs-Henseleit buffer (40 mM 
glucose, pH 7.4), continuously aerated (95 % O2 – 5 % CO2) and at 37 °C, in the presence, or 
absence, of verapamil (100 M), a P-gp inhibitor. After a 10-min equilibration period, everted 
sacs were filled (serosal side) with 1 ml of the same buffer containing RHO 123 (300 M). The 
serosal (basal) to mucosal (apical) transport of RHO 123 was evaluated by sampling aliquots of 
100 L of the buffer every 5 min for a 45-min period. The volume collected at each sampling 
moment was replaced by an equal volume of buffer solution, at the same temperature. At the 
end, the sacs were gently dried and weighted. Rhodamine 123 concentration was determined 
by spectrofluorometry (excitation/emission wavelength = 485/528 nm) in samples of mucosal 
medium, using a RHO 123 standard curve prepared in the same buffer solution. The excreted 













mucosal efflux rates were estimated from the slope (m) of the linear regression, and expressed 
in pmol of RHO 123 transported per mg of tissue. 
 
Assessment of P-glycoprotein transport activity in everted intestinal sacs in the presence of TX5 
The procedure was the same as described before, with minor alterations. Briefly, a set of 12 
hour-fasted Wistar Han rats was used. After anesthesia with a mixture of ketamine and 
xylazine (90/10 mg/kg b.w., respectively, ip), rats were placed in decubito supino position and 
the abdomen was opened. The duodenum or the ileocecal valve was identified and the 
proximal or the distal portion of the ileum was removed (20 cm approximately), gently rinsed 
with ice-cold saline solution (0.9 % NaCl) and immediately used to prepare everted intestinal 
sacs using an ice-cold plate. The everted intestinal sacs were placed in a chamber containing 
Krebs-Henseleit buffer (40 mM glucose, pH 7.4), continuously aerated (95 % O2 – 5 % CO2) and 
at 37 °C. Some sacs (mucosal side) were exposed to TX5 (20 M), while controls were exposed 
to 0.4 % DMSO (vehicle), both with or without the addition of verapamil (100 M). Everted 
sacs were allowed to equilibrate and then filled (serosal side) with 1 ml of the buffer 
containing RHO 123 (300 M). A direct contact between the drugs and the intestinal sac 
occurred throughout the experimental period. The serosal (basal) to mucosal (apical) transport 
of the fluorescent substrate was evaluated by sampling aliquots of 100 L of the buffer every 5 
min for a 45-min period. At the end, the sacs were gently dried and weighted. Rhodamine 123 
concentration was determined by spectrofluorometry (excitation/emission wavelength = 
485/528 nm) in samples of mucosal medium, using a RHO 123 standard curve prepared in the 
same buffer solution. The excreted amounts of RHO 123 into the mucosal side were plotted 
against the incubation time and the mucosal efflux rates were estimated from the slope (m) of 
the linear regression, and expressed in pmol of RHO 123 transported per mg of tissue. 













Assessment of P-glycoprotein transport activity in vivo after intraduodenal administration of 
TX5 
After the ex vivo experiments, we assessed P-gp activity in vivo after intraduodenal 
administration of TX5. For that purpose, we used digoxin as a P-gp substrate and evaluated its 
intestinal absorption in the presence or absence of TX5. After anesthesia with a mixture of 
ketamine and xylazine (90/10 mg/kg b.w., respectively, ip), the abdomen of the 12 hour-fasted 
rats was opened, the choledochal was blocked and both the duodenum and the portal vein 
were cannulated (Ghanem et al., 2011). Drugs (digoxin 0.025 mg/kg b.w. or digoxin+TX5 20 
M) were given intraduodenally in a final volume of 5 ml saline solution. The rat body 
temperature was controlled throughout the experimental period (37 °C). To quantify the portal 
content of digoxin, 400 L of blood was sampled every 10 min for a 60-min period after 
digoxin administration. After each sampling, an equal volume of saline was administered. 
Blood was centrifuged (10 000 x g, 15 min, room temperature) and the obtained plasma was 
used to determine digoxin concentration using a COBAS INTEGRA system (Roche Diagnostics).   
 
Statistical analysis 
Area under the curve (AUC) was calculated using the Phoenix® WinNonlin® software (Certara®, 
Princeton, USA). Statistical analysis was performed with the GraphPad Prism software program 
version 6 (San Diego, California, USA) and data presented as the means ± standard error of the 
mean (SEM). Outliers were identified using the ROUT test. The Shapiro–Wilk normality test 
was conducted before group comparison. Statistical comparison between groups was 
estimated using the parametric Student t-test, the non-parametric Mann-Whitney test or the 
two-way ANOVA parametric method followed by the Holm-Sidak or Tukey’s multiple 















P-gp was activated in vivo after TX5 administration by gavage 
We started the study by assessing the effect of TX5 over P-gp activity in vivo in a preliminary 
study. For this, a dose of 30 mg/kg, b.w., of TX5 hydrochloride associated to the prototypical P-
gp substrate digoxin (0.25 mg/kg, b.w.) was administered, by gavage, to Wistar Han rats. In this 
experimental approach, blood collected from the caudal vein at eight distinct time points for a 
seven-hour-period was used to quantify digoxin. Significant differences were found in digoxin 
plasma concentrations between TX5-treated and control rats (Figure 1), as showed by the 
significantly lower area under the curve (AUC) of digoxin in TX5-treated rats, when compared 
to controls (1463 ± 467 ng.min/ml versus 2238 ± 224.5 ng.min/ml, respectively).  
  
TX5 did not induce P-gp expression in the distal ileum of the rat intestine 
Since P-gp expression varies along the intestine, being the highest in the distal portion of the 
ileum (Doherty and Charman, 2002; Ghanem et al., 2011), we evaluated the effect of TX5 
hydrochloride (10 mg/kg b.w.) on P-gp expression levels in this portion of the rat ileum, 24 
hours after its administration by gavage. As can be observed in Figure 2, no differences on P-gp 
expression were found between BBM isolated from the distal portion of the intestine of 


















P-gp activity was not altered 24 h after TX5 administration in the distal ileum of the rat 
intestine  
After assessing the effect of TX5 over P-gp expression levels in the distal portion of the rat 
ileum, we studied the putative effect of TX5 over P-gp activity in the same conditions, i.e., 24 
hours after the administration of TX5 hydrochloride (10 mg/kg b.w.) by gavage. For that 
purpose, the rat everted intestinal sac was used as a reliable ex vivo model. The secretion of 
RHO 123, a typical P-gp fluorescent substrate, into the mucosal compartment of intestinal 
sacs, was evaluated at different time points. According to the obtained results, P-gp transport 
activity was unaffected in the distal ileum of rats pre-exposed to TX5 (Figure 3). 
 
TX5 increased P-gp activity in the distal ileum after a direct contact, but this effect was not 
observed in the proximal ileum  
To study whether TX5 was able to cause functional alterations in P-gp activity after a short-
term contact, we used everted intestinal sacs prepared from the distal ileum and a direct and 
immediate contact with TX5 (20 M) took place by adding the compound directly to the 
buffer-containing chamber. Since an activating effect was observed and because several other 
efflux carriers are known to exist in the ileum, the experiment was carried out in the presence 
and in the absence of verapamil, a P-gp inhibitor. As can be observed in Figure 4, TX5 
hydrochloride caused an almost two fold more increase in the efflux of RHO 123 (68.9±10.1; 
90.9±14.4; 106.9±17.2; 125.1±21.0 pmol/mg of tissue) when comparing with control sacs 
(39.5±5.3; 50.3±7.3; 60.7±8.7; 72.7±9.9 pmol/mg of tissue), effect that occurred from minute 















In order to verify if the activating effect observed in the distal portion of the rat ileum also 
occurred in the proximal portion, the same experimental approach was carried out by using 
everted intestinal sacs prepared from the proximal portion of the small intestine. The results 
obtained show that TX5 did not cause P-gp activation in the proximal portion (Figure 5A) and 
that the overall efflux of RHO 123 was significantly lower in this portion when compared to the 
distal portion (Figure 5B). 
 
P-gp was not activated in vivo after the intraduodenal administration of TX5 
To determine if the TX5-mediated activating effect observed ex vivo in the distal portion of the 
ileum can elicit consequences in the bioavailability of drugs or other xenobiotics that are P-gp 
substrates, the time-course changes in portal digoxin concentration was assessed after 
intraduodenal administration of a TX5 bolus. However, in vivo, no differences were found in 


















In recent years, our research group has being dedicated to disclose new compounds able to 
induce and/or activate P-gp in important barrier tissues, in order to find enhancers of safety of 
xenobiotics with potential to be used in intoxication scenarios. In fact, P-gp presents a wide 
range of structurally unrelated substrates and has a privileged location in crucial tissues, which 
underlies its involvement in the modulation of pharmaco(toxico)kinetic processes. As such, P-
gp often limits drug absorption and penetration into crucially important organs, such as the 
brain (Gameiro et al., 2017; Silva et al., 2015b). For this reason, under the toxicological point of 
view, ABC efflux transporters, namely P-gp, are relevant tools to take potentially harmful 
xenobiotics out of the cells, consequently reducing their toxicity (Gameiro et al., 2017). In this 
regard, we recently demonstrated the ability of some (thio)xanthonic compounds to increase 
both the expression levels and the activity of P-gp in the Caco-2 cell line, a human epithelial 
colorectal adenocarcinoma line that has been widely used as a model of the intestinal 
epithelial barrier, since it presents many properties typical of absorptive enterocytes (Sambuy 
et al., 2005).  
Five thioxanthones (TX1–5) and five dihydroxylated xanthones (X1–5) were shown to be, in the 
Caco-2 cell model, P-gp inducers and activators (Silva et al., 2015a; Silva et al., 2014b; Silva et 
al., 2015b). Particularly, Silva and colleagues showed that TX1-5 can promote the de novo 
synthesis of P-gp, as well as increase its efflux function, reducing, in consequence, the 
cytotoxicity of the harmful substrate, paraquat, towards Caco-2 cells (Silva et al., 2015a). It is 
known, however, that P-gp induction and activation not always occur simultaneously and that 
an increase in P-gp expression is not necessarily accompanied by a proportional increase in the 
pump activity. This independence was shown, for example, for colchicine (Silva et al., 2014a) 
and nonsteroidal anti-inflammatory drugs (Takara et al., 2009) in the Caco-2 cell model. 
Similarly, it is also possible the existence of an activating effect without any changes in the 













while activators enhance the transporter activity, although one compound can have 
overlapping mechanisms of action (Gameiro et al., 2017; Wessler et al., 2013).  
Considering the promising results obtained with TX5 (Silva et al., 2015a), which proved to be 
able to increase, in Caco-2 cells, P-gp expression by 208 % and activity by 198 %, as revealed by 
flow cytometry, we decided to further study the effects of this compound both ex vivo and in 
vivo. Furthermore, a relationship between expression and activity was shown to occur since 
the activity of P-gp was increased by 156 % in cells pre-exposed to TX5 for 24 h (Silva et al., 
2015a).  
The evaluation of the potential of a new compound to modulate P-gp activity in vivo is an 
integral part of drug development and is recommended by regulatory agencies  (Zhou et al., 
2019). Thus, we first conducted a preliminary in vivo study to assess the efficacy of TX5 
hydrochloride by administering, by gavage, a single high dose of the compound (30 mg/kg 
b.w.) to Wistar Han rats, evaluating its effects on the pharmacokinetics of digoxin (0.25 mg/kg 
b.w.). In fact, digoxin is a well-known P-gp substrate, which pharmacokinetics is well 
established, and thus has been being widely used in in vivo experiments (Bai et al., 2019; de 
Lannoy and Silverman, 1992; Fromm et al., 1999; Li et al., 2014; Oda and Murakami, 2017; 
Yang et al., 2016). Our in vivo study suggested a P-gp activator effect mediated by TX5, since 
the AUC of digoxin was significantly lower in TX5-treated rats when comparing to controls 
(1463 ± 467 ng.min/ml versus 2238 ± 224.5 ng.min/ml, respectively). The lower AUC of digoxin 
found in the plasma of rats administered with TX5 suggests a higher efflux of digoxin at the 
intestinal barrier after its administration by gavage. This effect might be related with a higher 
activity of P-gp expressed in the intestine as consequence of a direct and immediate activation 
of the efflux protein by TX5. Overall, this effect was translated in a significantly lower AUC of 













Given the in vivo confirmation of the TX5-mediated P-gp activating effect previously observed 
in vitro (Silva et al., 2015a), we proceeded to a preliminary safety assessment of the compound 
(Rocha-Pereira et al., 2019).  
Despite the absence of apparent signs of discomfort or toxicity, we found TX5 (30 mg/kg b.w.) 
to cause relevant toxicity after a complete histopathological analysis. An extensive hepatic 
necrosis, splenic parenchyma hyperemia, signs of red pulp hemorrhage, slight myocardium 
hyperemia, small intestine inflammation, as well as renal tubular edema and slight hyperemia 
were observed (Rocha-Pereira et al., 2019). These findings led to a dose reduction of TX5 to be 
used in subsequent safety assessment assays. This selected lowest dose (10 mg/kg b.w.) did 
not induce considerable toxicity in the biological matrices studied (Rocha-Pereira et al., 2019), 
which justified its use in the functional studies described in the present study.  
It should be noted that the initial evaluation of the effect of the compound in vivo, using the 30 
mg/kg dose described in this study, occurred immediately after administration, by gavage, of 
TX5 or TX5 plus digoxin, and lasted for 12 hours. As such, the activation effect was observed 
shortly after administration and, therefore, unaffected by the potential toxicity of the 
compound at this dose (30 mg/kg b.w.) (Rocha-Pereira et al., 2019). 
It is known that there is a regional difference of P-gp activity in the intestinal tract and that the 
expression levels of P-gp greatly vary along the small intestine, being the highest in the distal 
ileum and the lowest in the proximal portion (Doherty and Charman, 2002; Iida et al., 2005; Li 
et al., 2015). For that reason, we decided to start the study of the effects of TX5 on P-gp 
expression levels using the portion of the ileum where the expression pattern of the 
transporter is the most expressive. In the present study, we did not observe any effect of the 
compound on the carrier expression levels. This  effect was evaluated by western blot in BBM 
of the rat distal ileum, 24 hours after the administration, by gavage, of TX5 hydrochloride (10 













found in vitro, 24 hours after exposure to TX5, an effect observed by flow cytometry and 
subsequently corroborated by western blot (Silva et al., 2015a).  
Although the mechanism of action of P-gp inducers remains unclear, it is known that P-gp 
induction is complex and regulated by distinct nuclear factors. Some of them are the pregnane 
X receptor (PXR), constitutive androstane receptor (CAR), nuclear factor erythroid-derived 2-
related factor (Nrf2), Y-box binding protein-1 (YB-1), nuclear factor Y (NF-Y), nuclear factor-κB 
(NF-κB), liver X receptor (LXR), farnesoid X receptor (FXR) and peroxisome proliferator-
activated receptors α and γ (PPARα and PPARγ) (Gameiro et al., 2017). Possibly, a time-point of 
24-hours after TX5 hydrochloride administration may not be sufficient to observe in vivo 
changes in the P-gp expression pattern. The choice of this time-point was based in the results 
obtained in vitro, for which a prominent inducing P-gp effect was observed (Silva et al., 2015a). 
In fact, 24 hours of incubation of cells were needed to observe a potent in vitro TX5-mediated 
inducing effect (Silva et al., 2015a). However, it will be legitimate to expect the need for a 
longer period to observe this induction effect, in vivo. Accordingly, the study performed by 
Martignoni et al. showed that the expression of cytochrome P450 enzymes can be similarly 
induced both in vitro and in vivo, although a greater time of exposure to the inducer is 
required when the effect is seen in vivo (6 to 24 hours versus 3 days, respectively) (Martignoni 
et al., 2004). Additionally, it is known that there are interspecies differences in P-gp expression 
levels (Han et al., 2018; Myllynen et al., 2010). As such, we can consider the existence of 
putative differences in the pattern of expression of P-gp between the human Caco-2 cell model 
and the rat everted intestinal sac that could ultimately explain our results.  Nevertheless, the 
results of the expression herein presented were in agreement with the results obtained in 
BBM, 24 hours after exposure of the animals to TX5 hydrochloride (10 mg/kg b.w., gavage). 
The absence of inducing effects in the BBM prepared from the distal portion of the ileum was 
accompanied by a corresponding absence of functional alterations at the level of the 













mucosal cumulative efflux of RHO 123 were registered between TX5-treated and control 
everted intestinal sacs. In fact, changes in carrier activity due to expression levels changes are 
expected to occur, although, as previously mentioned, a causal relationship between both 
might not exist. The study performed by Ghanem et al. described an increased P-gp 
functionality in the distal ileum in response to an inducing effect advocated by acetaminophen 
(Ghanem et al., 2011). Accordingly, the study carried out by Silva and co-authors also 
demonstrated the influence of a previous increase of P-gp expression on the activity of the 
transporter. These TX5-triggered effects therefore resulted in less paraquat-mediated 
cytotoxicity in Caco-2 cells (Silva et al., 2015a). However, the results of the study herein 
presented, while consistent, indicate the absence of TX5-induced changes in both P-gp 
expression and activity, 24 hours after exposure to the compound. Considering that inducers 
and activators act by distinct mechanisms of action, the absence of inducing effects of P-gp 
expression observed in the present study did not exclude the possibility of a TX5-mediated 
activating effect. As previously stated, the regulation of the expression of a given protein is a 
very complex process, while the activation implies the binding of a compound to the carrier, 
enabling the binding of the substrate to another site and promoting, in consequence, its 
transport across the membrane (Gameiro et al., 2017). This is, apparently, a much simpler 
process that involves the nucleotide binding domains, not implying the participation of any 
nuclear factor.  
Thus, we used the same experimental ex vivo approach to study the putative TX5-mediated P-
gp activating effect both in the distal and the proximal portions of the rat ileum, after a short-
term and direct contact between the compound and the everted intestinal sac. Again, we 
started by testing the effect of TX5 in the distal portion of the rat ileum, where P-gp expression 
levels are highest. We intended to evaluate the immediate modulatory effect of TX5 in the 
activity of P-gp expressed at the apical membrane of rat ileum enterocytes, using everted 













contact between the compound and the intestinal sac was desired, the same concentration of 
TX5 tested in vitro (20 M) was chosen (Silva et al., 2015a). Very importantly, and in 
accordance with our previous in vitro data, TX5 (20 M) caused a significantly higher serosal to 
mucosal secretion of RHO 123 in the distal portion of the rat ileum, as a result of a direct P-gp 
activation. This effect was completely abolished by the P-gp inhibitor verapamil (100 M). 
However, this increased transport activity was time-dependent since it became apparent only 
from minute 30 on. This fact suggests the need for a certain time of contact with the activator 
before the effect becomes measurable. A similar observation took place in another study, 
where the acetaminophen-mediated P-gp activating effect in the rat distal ileum was 
registered 20 min after filling the sacs with RHO 123 (Ghanem et al., 2011).  
In the present study, and in opposition to the distal portion, no TX5 activating effects occurred 
in the proximal portion. This finding highlights the possibility for a differential activating effect 
mediated by the compound in the two portions of the ileum. Furthermore, considering the 
overall smaller efflux of RHO 123 in the proximal portion of the intestine, it becomes more 
difficult to see potential differences elicited by TX5 as consequence of its activating effect.  
Given the P-gp activating effect triggered by TX5 in the distal portion of the rat ileum, we 
decided to go further by studying the putative effect of the compound over P-gp activity in 
vivo. Indeed, given the relevance of P-gp at the intestine, where it limits drug absorption, we 
hypothesized that its direct activation at the intestinal barrier in vivo could constitute a 
valuable therapeutic approach to reduce xenobiotics absorption, namely those with relevant 
toxicity. However, our expectations were not confirmed since no differences in the 
concentrations of digoxin in the portal vein plasma were found between anesthetized rats 
administered only with digoxin and those where digoxin and TX5 hydrochloride were co-
administered directly in the duodenum. This methodology was previously used by Ghanem 
and colleagues, allowing the detection of differences in digoxin plasma concentration in 













administration (Ghanem et al., 2011). This effect was justified by the acetaminophen-mediated 
inducing effect of P-gp expression on both intestinal portions, although particularly prominent 
in the proximal region. Likewise, and despite the absence of P-gp inducing effects triggered by 
TX5 in our experimental conditions, we may consider that the lack of functional effects on P-gp 
activity in vivo is closely related to the heterogeneity of the intestine with respect to P-gp 
expression (Li et al., 2017). In fact, we should consider the possibility that the observed effect 
is exclusively a consequence of exchanges in the proximal portion of the small intestine, where 
basal P-gp expression levels are the lowest and where no inducing or activating effects were 
observed. Alternatively, the differentiated modulation mediated by TX5 observed ex vivo may 
mask some activating effect in vivo. These hypotheses require further research. Nevertheless, 
it is important to emphasize that the conditions used in this in vivo study were different from 
that used in the in vivo preliminary study, namely the methodology used, the time points 
considered and the dose of the compound tested. All these factors may be contributing to the 
differences found. 
Taken together, our data might indicate a TX5-mediated activation effect only observable in 
the distal portion of the rat ileum and when a direct contact between the compound and the 
everted intestinal sac takes place. The translation of this finding to humans will, however, 
require further investigation since it is known that there are species differences in P-gp 
abundance, already demonstrated for humans and rats (Li et al., 2017). Additionally, it is 
known that the absorption of the majority of drugs is initiated in the duodenum (Shugarts and 
Benet, 2009), which may condition the impact of the activating effect observed in the most 
distal portion of the ileum. Nevertheless, our findings i) suggest that TX5 can differently 
modulate P-gp activity in the rat intestinal barrier; ii) demonstrate that TX5 can differently 
modulate P-gp activity in distinct portions of the rat ileum ex vivo; iii) support a greater P-gp 
activity under TX5 stimulation in the distal portion of the rat ileum. These findings may open 













development of new antidotal strategies or therapeutic adjuvants in the pharmacological 




This work was supported by the Norte Portugal Regional Operational Programme 
(NORTE2020), under the PORTUGAL 2020 Partnership Agreement (DESignBIOtecHealth—New 
Technologies for three Health Challenges of Modern Societies: Diabetes, Drug Abuse and 
Kidney Diseases) and was developed under the Project NORTE-01-0145-FEDER-000024; the 
COMPETE 2020, Portugal 2020, European Union through the ERDF and FCT (Project No. POCI-
01-0145-FEDER-028736); and the FCT/MCTES (UID/MULTI/04378/2019). 
 
REFERENCES 
Bai J, Zhao S, Fan X, Chen Y, Zou X, Hu M, Wang B, Jin J, Wang X, Hu J, Zhang D and Li Y (2019) 
Inhibitory effects of flavonoids on P-glycoprotein in vitro and in vivo: Food/herb-drug 
interactions and structure-activity relationships. Toxicol Appl Pharmacol 369:49-59. 
de Lannoy IA and Silverman M (1992) The MDR1 gene product, P-glycoprotein, mediates the 
transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 189:551-
557. 
Dinis-Oliveira RJ, Duarte JA, Remiao F, Sanchez-Navarro A, Bastos ML and Carvalho F (2006a) 
Single high dose dexamethasone treatment decreases the pathological score and 
increases the survival rate of paraquat-intoxicated rats. Toxicology 227:73-85. 
Dinis-Oliveira RJ, Remiao F, Duarte JA, Ferreira R, Sanchez Navarro A, Bastos ML and Carvalho F 
(2006b) P-glycoprotein induction: an antidotal pathway for paraquat-induced lung 
toxicity. Free Radic Biol Med 41:1213-1224. 
Doherty MM and Charman WN (2002) The mucosa of the small intestine: how clinically 
relevant as an organ of drug metabolism? Clin Pharmacokinet 41:235-253. 
Flecknell PA, Liles JH and Williamson HA (1990) The use of lignocaine-prilocaine local 
anaesthetic cream for pain-free venepuncture in laboratory animals. Lab Anim 24:142-
146. 
Fromm MF, Kim RB, Stein CM, Wilkinson GR and Roden DM (1999) Inhibition of P-glycoprotein-
mediated drug transport: A unifying mechanism to explain the interaction between 
digoxin and quinidine [seecomments]. Circulation 99:552-557. 
Gameiro M, Silva R, Rocha-Pereira C, Carmo H, Carvalho F, Bastos ML and Remiao F (2017) 
Cellular Models and In Vitro Assays for the Screening of modulators of P-gp, MRP1 and 













Ghanem CI, Arias A, Novak A, Carpini GD, Villanueva S, Blazquez AG, Marin JJ, Mottino AD and 
Rubio MC (2011) Acetaminophen-induced stimulation of MDR1 expression and activity 
in rat intestine and in LS 174T human intestinal cell line. Biochem Pharmacol 81:244-
250. 
Gottesman MM, Fojo T and Bates SE (2002) Multidrug resistance in cancer: role of ATP-
dependent transporters. Nature reviews Cancer 2:48-58. 
Gupta P, Garg T, Tanmay M and Arora S (2015) Polymeric Drug-Delivery Systems: Role in P-gp 
Efflux System Inhibition. Critical reviews in therapeutic drug carrier systems 32:247-
275. 
Han LW, Gao C and Mao Q (2018) An update on expression and function of P-gp/ABCB1 and 
BCRP/ABCG2 in the placenta and fetus. Expert Opin Drug Metab Toxicol 14:817-829. 
Iida A, Tomita M and Hayashi M (2005) Regional difference in P-glycoprotein function in rat 
intestine. Drug Metab Pharmacokinet 20:100-106. 
Juliano RL and Ling V (1976) A surface glycoprotein modulating drug permeability in Chinese 
hamster ovary cell mutants. Biochim Biophys Acta 455:152-162. 
Kessler M, Acuto O, Storelli C, Murer H, Muller M and Semenza G (1978) A modified procedure 
for the rapid preparation of efficiently transporting vesicles from small intestinal brush 
border membranes. Their use in investigating some properties of D-glucose and 
choline transport systems. Biochim Biophys Acta 506:136-154. 
Li M, de Graaf IA, de Jager MH and Groothuis GM (2015) Rat precision-cut intestinal slices to 
study P-gp activity and the potency of its inhibitors ex vivo. Toxicol In Vitro 29:1070-
1078. 
Li M, de Graaf IA, de Jager MH and Groothuis GM (2017) P-gp activity and inhibition in the 
different regions of human intestine ex vivo. Biopharm Drug Dispos 38:127-138. 
Li X, Hu J, Wang B, Sheng L, Liu Z, Yang S and Li Y (2014) Inhibitory effects of herbal 
constituents on P-glycoprotein in vitro and in vivo: herb-drug interactions mediated via 
P-gp. Toxicol Appl Pharmacol 275:163-175. 
Lima RT, Sousa D, Gomes AS, Mendes N, Matthiesen R, Pedro M, Marques F, Pinto MM, Sousa 
E and Vasconcelos MH (2018) The Antitumor Activity of a Lead Thioxanthone is 
Associated with Alterations in Cholesterol Localization. Molecules 23:1-19. 
Lima RT, Sousa D, Paiva AM, Palmeira A, Barbosa J, Pedro M, Pinto MM, Sousa E and 
Vasconcelos MH (2016) Modulation of Autophagy by a Thioxanthone Decreases the 
Viability of Melanoma Cells. Molecules 21. 
Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin 
phenol reagent. J Biol Chem 193:265-275. 
Martignoni M, de Kanter R, Grossi P, Mahnke A, Saturno G and Monshouwer M (2004) An in 
vivo and in vitro comparison of CYP induction in rat liver and intestine using slices and 
quantitative RT-PCR. Chem Biol Interact 151:1-11. 
Mottino AD, Hoffman T, Jennes L and Vore M (2000) Expression and localization of multidrug 
resistant protein mrp2 in rat small intestine. J Pharmacol Exp Ther 293:717-723. 
Murphy SJ, Smith P, Shaivitz AB, Rossberg MI and Hurn PD (2001) The effect of brief halothane 
anesthesia during daily gavage on complications and body weight in rats. Contemp Top 
Lab Anim Sci 40:9-12. 
Myllynen P, Kummu M and Sieppi E (2010) ABCB1 and ABCG2 expression in the placenta and 
fetus: an interspecies comparison. Expert Opin Drug Metab Toxicol 6:1385-1398. 
Oda K and Murakami T (2017) Pharmacokinetic interaction of green tea beverage containing 
cyclodextrins and high concentration catechins with P-glycoprotein substrates in LLC-
GA5-COL150 cells in vitro and in the small intestine of rats in vivo. J Pharm Pharmacol 
69:1736-1744. 
Paiva AM, Pinto MM and Sousa E (2013) A century of thioxanthones: through synthesis and 













Palmeira A, Vasconcelos MH, Paiva A, Fernandes MX, Pinto M and Sousa E (2012) Dual 
inhibitors of P-glycoprotein and tumor cell growth: (re)discovering thioxanthones. 
Biochem Pharmacol 83:57-68. 
Rocha-Pereira C, Silva V, Costa VM, Silva R, Garcia J, Gonçalves-Monteiro S, Duarte-Araújo M, 
Santos-Silva A, Coimbra S, Dinis-Oliveira RJ, Lopes C, Silva P, Long S, Sousa E, Bastos ML 
and Remião F (2019) Histological and toxicological evaluation, in rat, of a P-
glycoprotein inducer and activator:  1-(propan-2-ylamino)-4-propoxy-9 H -thioxanthen-
9-one (TX5). EXCLI Journal 18:697-722. 
Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A and Zucco F (2005) The Caco-2 cell 
line as a model of the intestinal barrier: influence of cell and culture-related factors on 
Caco-2 cell functional characteristics. Cell Biol Toxicol 21:1-26. 
Shugarts S and Benet LZ (2009) The role of transporters in the pharmacokinetics of orally 
administered drugs. Pharm Res 26:2039-2054. 
Silva R, Carmo H, Dinis-Oliveira R, Cordeiro-da-Silva A, Lima SC, Carvalho F, Bastos Mde L and 
Remiao F (2011a) In vitro study of P-glycoprotein induction as an antidotal pathway to 
prevent cytotoxicity in Caco-2 cells. Arch Toxicol 85:315-326. 
Silva R, Carmo H, Vilas-Boas V, Barbosa DJ, Palmeira A, Sousa E, Carvalho F, Bastos Mde L and 
Remiao F (2014a) Colchicine effect on P-glycoprotein expression and activity: in silico 
and in vitro studies. Chemico-biological interactions 218:50-62. 
Silva R, Carmo H, Vilas-Boas V, de Pinho PG, Dinis-Oliveira RJ, Carvalho F, Silva I, Correia-de-Sa 
P, Bastos Mde L and Remiao F (2013) Doxorubicin decreases paraquat accumulation 
and toxicity in Caco-2 cells. Toxicol Lett 217:34-41. 
Silva R, Palmeira A, Carmo H, Barbosa DJ, Gameiro M, Gomes A, Paiva AM, Sousa E, Pinto M, 
Bastos Mde L and Remiao F (2015a) P-glycoprotein induction in Caco-2 cells by newly 
synthetized thioxanthones prevents paraquat cytotoxicity. Arch Toxicol 89:1783-1800. 
Silva R, Sousa E, Carmo H, Palmeira A, Barbosa DJ, Gameiro M, Pinto M, Bastos Mde L and 
Remiao F (2014b) Induction and activation of P-glycoprotein by dihydroxylated 
xanthones protect against the cytotoxicity of the P-glycoprotein substrate paraquat. 
Arch Toxicol 88:937-951. 
Silva R, Vilas-Boas V, Carmo H, Dinis-Oliveira RJ, Carvalho F, Bastos ML and Remião F (2011b) P-
glycoprotein induction by hypericin protects Caco-2 cells against paraquat toxicity. 
Toxicology Letters 205:S93-S94. 
Silva R, Vilas-Boas V, Carmo H, Dinis-Oliveira RJ, Carvalho F, de Lourdes Bastos M and Remiao F 
(2015b) Modulation of P-glycoprotein efflux pump: induction and activation as a 
therapeutic strategy. Pharmacol Ther 149:1-123. 
Takara K, Hayashi R, Kokufu M, Yamamoto K, Kitada N, Ohnishi N and Yokoyama T (2009) 
Effects of nonsteroidal anti-inflammatory drugs on the expression and function of P-
glycoprotein/MDR1 in Caco-2 cells. Drug and chemical toxicology 32:332-337. 
Tian X, Chang Y, Wei J, Liu R, Wang L, Zhang J and Zhang X (2019) Baicalin reduces ciclosporin 
bioavailability by inducing intestinal p-glycoprotein in rats. J Pharm Pharmacol 71:788-
796. 
Vilas-Boas V, Silva R, Palmeira A, Sousa E, Ferreira LM, Branco PS, Carvalho F, Bastos Mde L and 
Remiao F (2013) Development of novel rifampicin-derived P-glycoprotein 
activators/inducers. synthesis, in silico analysis and application in the RBE4 cell model, 
using paraquat as substrate. PLoS One 8:e74425. 
Wessler JD, Grip LT, Mendell J and Giugliano RP (2013) The P-glycoprotein transport system 
and cardiovascular drugs. J Am Coll Cardiol 61:2495-2502. 
Yang B, Ma LP, Ma W, Wei SJ, Ji HY, Li HG, Dang HW, Liu C, Wu XL and Chen J (2016) A self -
contrast approach to evaluate the inhibitory effect of chrysosplenetin, in the absence 
and presence of artemisinin, on the in vivo P-glycoprotein-mediated digoxin transport 













Yigitaslan S, Erol K and Cengelli C (2016) The Effect of P-Glycoprotein Inhibition and Activation 
on the Absorption and Serum Levels of Cyclosporine and Tacrolimus in Rats. Adv Clin 
Exp Med 25:237-242. 
Zhou T, Arya V and Zhang L (2019) Comparing Various In Vitro Prediction Methods to Assess 


















Figure 1 – Digoxin plasma concentration in control and TX5-treated rats. Animals were administered, by 
gavage, with digoxin (0.25 mg/kg) or digoxin (0.25 mg/kg) + TX5 hydrochloride (30 mg/kg). Digoxin 
concentration in different time points was quantified in plasma samples obtained from blood collected 
from the caudal vein, using an AutoAnalyzer (PRESTIGE® 24i, PZ Cormay S.A.). Data are presented as 
means ± SEM of five rats per group. Statistical comparisons were made using the two-way ANOVA 
followed by the Holm-Sidak multiple comparisons test (*** p< 0.001; **** p< 0.0001 for TX5-treated 




Figure 2. Western blot analysis of P-gp expression levels in the brush border membranes (BBM) of the 
distal i leum of rats orally exposed to TX5 hydrochloride (10 mg/kg) for 24 h. Western blot study of P-gp 













exposed rats. Representative images of Western blot analysis of P-gp (170 kDa) immunocontent (A) and 
respective densitometric analysis (B) are shown. Densitometric analysis  are expressed as percentage of 
control  and presented as means ± SEM of at least four rats per condition. Statistical comparisons were 




Figure 3. Effect of TX5 on P-gp activity 24 h after administration. P-gp-mediated RHO 123 efflux was 
measured ex vivo using 10-cm everted sacs from distal i leum of control and TX5-exposed (10 mg/kg 
b.w.) rats (24 h). The sacs were fi l led with RHO 123 (300 M; serosal side). The dye secreted into the 
outside compartment (mucosal side) was assessed every 5 min for 45 min. Data are presented as means 
± SEM of at least ten rats per group. The excreted amounts of RHO 123 into the mucosal side were 
plotted against the incubation time and the mucosal efflux rates were estimated from the slope (m) of 
the linear regression, and expressed in pmol of RHO 123 transported per mg of tissue. Statistical 
comparisons were made using the two-way ANOVA parametric method followed by the Tukey’s 















Figure 4. Short-term and direct effect of TX5 on P-gp activity in rat distal i leum. P-gp-mediated RHO 123 
efflux was measured ex vivo using 10-cm everted sacs from the distal i leum of rats. The sacs were fi l led 
with RHO 123 (300 M; serosal side). The dye secreted into the outside compartment (mucosal side) 
was assessed every 5 min up to 45 min, in the presence or absence of TX5 (20 M) and VER (100 M). 
Data are presented as means ± SEM of six to eleven rats per group. The excreted amounts of RHO 123 
into the mucosal side were plotted against the incubation time and the mucosal efflux rates were 
estimated from the slope (m) of the linear regression, and expressed in pmol of RHO 123 transported 
per mg of tissue. Statistical comparisons were made using the two-way ANOVA parametric method 
followed by the Tukey’s multiple comparisons post hoc test. VER - verapamil. *p <0.05; **p <0.01; ***p 
<0.001; 
****








Figure 5. Short-term and direct effect of TX5 on P-gp activity in rat proximal i leum (A) and the overall  
efflux of RHO 123 in the distal and proximal portions of the rat i leum in the absence of TX5  (B). P-gp-













distal (B) i leum of rats.  The sacs were fi l led with RHO 123 (300 M; serosal side). The dye secreted into 
the outside compartment (mucosal side) was assessed every 5 min for 45 min, in the presence or 
absence of TX5 (20 M) (A). Data are presented as means ± SEM of seven to ten rats per group. The 
excreted amounts of RHO 123 into the mucosal side were plotted against the incubation time and the 
mucosal efflux rates were estimated from the slope (m) of the linear regression, and expressed in pmol 
of RHO 123 transported per mg of tissue. Statistical comparisons were made using the two-way ANOVA 
parametric method followed by the Tukey’s  or Sidak's multiple comparisons post hoc test. 
 
 
Figure 6. Effect of TX5 on digoxin absorption. Net intestinal absorption of digoxin was indirectly 
determined by changes in portal plasma concentrations over 60 min after intraduodenal administration 
of digoxin in anesthetized control (digoxin 0.025 mg/kg) and TX5-treated rats (digoxin 0.025 mg/kg + TX5 
20 M). Data are presented as means ± SEM of eight to nine rats  per group. Statistical comparisons 
were made using the two-way ANOVA parametric method followed by the Holm-Sidak multiple 
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 P-glycoprotein (P-gp) is a carrier efflux protein. 
 TX5 increases P-gp expression and activity in vitro. 
 TX5 activates P-gp only at the distal portion of the rat ileum, ex vivo. 
 TX5 seems to modulate, in vivo, the AUC of P-gp substrates. 
Jo
ur
na
l P
re
-p
ro
of
Journal Pre-proof
